CFM
ZNTL icon

Catalyst Funds Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Catalyst Funds Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.1K Buy
+16,700
New +$43.1K 0.01% 555
2025
Q4 		– Sell
-51,400
Closed -$77.6K – 588
2025
Q3 		$77.6K Buy
51,400
+24,600
+92% +$36.9K 0.01% 468
2025
Q2 		$31.1K Buy
+26,800
New +$35.3K 0.01% 402
2024
Q3 		– Sell
-3,500
Closed -$14.3K – 1642
2024
Q2 		$14.3K Sell
3,500
-5,800
-62% -$64.8K ﹤0.01% 799
2024
Q1 		$147K Buy
+9,300
New +$128K 0.04% 319

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Catalyst Funds Management's ZNTL Position: Q1 2026 in Review

Catalyst Funds Management opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 16,700 shares worth $39.1K. The stake represents 0.01% of the portfolio and ranks #555 among its holdings. This is a return to the name: Catalyst Funds Management previously reported a position in ZNTL as recently as Q3 2025.

Catalyst Funds Management first reported a position in ZNTL in Q1 2024 and has held it in 5 quarters since. The position peaked at $147K in Q1 2024. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Catalyst Funds Management held 16,700 shares of Zentalis Pharmaceuticals worth $39.1K as of Q1 2026.
  • Zentalis Pharmaceuticals was a new Catalyst Funds Management position in Q1 2026.
  • Zentalis Pharmaceuticals made up 0.01% of Catalyst Funds Management's portfolio in Q1 2026, its #555 holding.
  • Catalyst Funds Management first reported a position in Zentalis Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
  • Catalyst Funds Management's Zentalis Pharmaceuticals position peaked at $147K in Q1 2024.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.